will merck continue to do that?hey are continuing to look at all opportunities, in the acute hospital setting, what they call this antibiotics and other things given in hospital and other areas in which they're working including cancer, the conference that we're here now, focus on cancer and presenting data on a drug. merck still looking, not looking to do big industry consolidation-type deal but will continue to buy. back to you. >> very valuable insights from merck ceo. meg tirrell, thank you. caught up with michael boni one year ago, we asked about the possibility of an acquisition. >> we built a strong track record of being thoughtful, about what we invest in but once we invest we go hard at it and develop data that the clinical, physicians in the world need, and able to do that with enough margin so that we can continue to attract capital we need. maybe it happens, maybe it doesn't. but i can't control that. >> hint there from the cubist ceo. multibillion pharma deal. >> it's interesting, meg mentioned, seven y

merck buying the company. meg terrell was ahead of the story on friday telling us a deal was in the works. she is in san francisco at one of the biggest cancer meetings of the year and scored a live interview with merck's ceo. >> thank you so much. let's bring in ken frazier, the ceo of merck. thank you for joining us. >> thank you, meg, for having me. always good to be on cnbc. >> well, so this is a big deal in a space that has been a tough area, antibiotics and a huge public health need. tell us why this makes sense for merck. >> every year in this country about 2 million people have a form of infection that is resistant to conventional antibiotics. about 23,000 of those people die. so these kinds of infections are critically important in our society. so this is a great opportunity for us because merck has been committed to the field of antibiotic research for 70 years. and cubist has also been a leader in this area bringing forward novel antibiotics that can be useful in the context of growing global resist

merck for cubist. of course with this deal merck brings in a lot of antibiotics. another drug that is expected to be approved by the fda this month. which could bring in $9.5 billion. $102 a share merck for cubist just hitting now. back to you guys. >> all right. meg, are you going to be with us later to talk about the pd-1 blockers? >> yeah. that's why we're sitting in this empty convention center which should get busier today. we'll be hear to talk about the humanology meeting. >> i know cubist is working on all sorts of new antibiotic treatments but how far along are they and what do they have up their sleeves so we understand what merck is actually getting? >> yeah. so they've got the approved drug cubesin. the other one is for infections known as gram negatives. but there aren't a lot of drugs out there for it. with this growing superbug problem, a lot are becoming resistant to certain drugs. this one is expected to be approved and could get $1.5 b billion. it also has a drug that helps patients recover faster from bowel surgery helping them get out of the ho

in a down market, the news sent merck shares up fractionally and cubist stock soaring 35%. meg terrell explains why the deal is putting renewed attention on an often ignored part of the drug market. >> drug giant merck is making a big move in an area abandoned by many large drugmakers. the company's paying almost $10 billion to acquire cubist pharmaceuticals, a maker of antibiotics. it's been a tough area for drug development in recent years as regulatory hurdles and low return on investment has driven many companies away. >> all big farm ma companies eliminated their discovery capabilities and very few of them even market antibiotics. >> reporter: as bacteria become restibt to existing drugs becoming what are known as superbugs policymakers and companies are responding to a growing public health threat. >> every year in this country about 2 million people have a form of infection that's resistant to conventional antibiotics. about 23,000 of those people die. >> reporter: with cubist merck gets the billion dollar a year antibiotic cubison. cubist is expected to receive appr

>> merck reached out to cubist and expressed a strong interest. board at cubist sort of validated merck as a buyer, got some clarity on how much value they saw in the company and what kind of conditions they would put in place for the close. that point decided we should check with other potential buyers and ultimately they decided to accept the offer. >> were there other bids? >> there were. >> is or anything you can go into detail about? >> not at this time. >> did you build the company with an eye to sell? or did it come as a surprise even to you? >> we have long built the company as a stand-alone entity. workve always said that we for the shareholders, so while our strategy was to build an independent company, for the 13 years i have been here we have been very clear that if taste tj buyer or financial buyer decided that they could deliver better risk-adjusted returns to our shareholders that we could, we would have to take that seriously. i think that that is what has transpired here. >> what does cubist have in the pipeline did you think is m

i'm raising both eyebrows on this at merck so no one at merck would say jim dumped on us and said we are idiots and morons and why didn't we wait. i'm not going there. i'm not calling them idiots, morons or fools, i'm just saying it raises eyebrows. >> i think that was very well stated, jim with. >> i'm not gandhi. i know that. >> no. you're not saying they got pantsed or anything like that. >> that march to the sea was nasty. >> david, what's coming up at the ubs conference later today. >> we are going to be talking to chris albrecht. a lot of takeover speculation involving starz. we'll ask about that and other things about their original programming. netflix got that "marco polo" show. starz originally had an opportunity at that. and david zaslav who runs discovery. you want to talk about the bundle and over the top. a key issue is good old-fashioned advertising. whether it's still going to be there in the way it was previously or whether we are seeing something of a new world and ratings with it. later today jeff bewkes will be my guest. first time he's spoken on tv, i believe it

merck is looking to buy cubist for more than $7 billion. another break after the cancer news from merck. >>> and oil prices falling to a four-year low now. down a dollar since early may. >>> and a british invasion. the royals have arrived. william and kate on a whirlwind trip to new york. the u.k. has them, we have the kardashians. it is monday, december 8, 2014. "squawk box" begins right now. >>> good morning, everybody. welcome to "squawk box" on cnbc. i'm becky quick along with joe kernan and andrew ross-sore kip. here are the three big stories we are watching today. stocks are on a big winning streak with the dow closing in on 18,000. november seeing the strongest job gains in 35 months. but could good news actually be bad news? we sure hope not. we'll get reaction to friday's employment report. investors immediately reprice expectations for the fed rate hike from june to september. >>> and while we were sleeping there, were a number of key economic reports out of asia. china trade data was weak and japan's third quarter gdp showed the

in cramer puts the deal under the microscope. >>> three cheers for merck.nk this morning's purchase of cubist may be a great deal. cubist has the latest and greatest formulations to treat super bugs and before a tragic experience, i would have no idea why merck would pay the price. first, we've had the cubist ceo on many times and he impressed me going after unmet needs, diseases unique to hospital patient whose watch them after they have been admitted and often killed by them. that's right, a hospital is basically a breeding ground for treatment of viruses and bacteria. i didn't understand it. we know no matter how fabulous a drug might be, margins get killed and takes the stock down with it but management made it clear that the company's pipeline was filled with new drugs that could attack diseases specific to hospital stays. and in particular, it was well ahead of everyone else with important face three trials that can make a real difference. each time i spoke to management, i was astounded at the size of the unmet needs here and the compelling logic of

with respect to the vaccine merck is faring with these are early days of. this is the virus that is designed so that there is active cycles of replication of the vaccine vector when it is in the human host and that has the advantage of prompting a real immune system fast. we have to watch carefully for side effects so that we are alert to things that could signal reactive -- something that would be a harbinger of a more serious issue down the road. i think we also anticipate the creation of a solution to this is going to have to be pragmatic. lives are at stake today while we are sitting here having this scientific conversation and we can't move at the pace we are used to moving. i don't know about my colleagues and other manufacturing pharmaceutical companies that this is an incredible destructor of business as usual because we have to be pragmatic. we can't take our time. we can't have a lot of conference calls and meetings and do all the stakeholders and key opinion leader engagement on and on. we have to do them in parallel. we have to work faster to mo

in a deal to battle superbugs, merck is buying cuba's pharmaceutical for $4.8 billion. combat bacterial infections and other types of treatment. jeff mccracken points out the clack -- points out to -- >> there are bacteria that builds up resistance to penicillin. he you need new drugs to combat these viruses. that is what merck is trying to .o with this cubist acquisition >> cubist hopes to have four new antibacterial drugs by 2020? u.s.ald's saw its worse sale decline in a decade last month. they are struggling to compete. an expired meat scandal in asia has hurt sales. lending club has boosted the sales price of shares in its ipo. the committee plans to all the shares at $14 each, originally offering them for $12 apiece. lending club is expected to start trading thursday on the new york stock exchange. and nintendo may have something to celebrate this christmas. after losing nearly $200 million last year, became maker is making a comeback. they expect to sell 3.6 million wii u consuls this year. to our lead, new details behind sony's massive cyber attack. news has lea

merck is saying, it is something we want to get into. a billion that former world, a mere trifling amount of money compared to some of the numbers. $7 billion. pharma merkel wants to do the small to midsized acquisitions. pretty advanced. >> what does it tells about merck's strategy? >> merck is not pursuing the megadeal strategy which others seem to be doing. ra.zer had a try with ast they tried with another and that did not work. in normal sleep and vicious transactions that may or may not get to the point may or mayment, they not happen. merck is setting its sights a bit lower and smaller and more manageable. you can argue that is strategy that will succeed given some of the obstacles in the huge transactions. >> i am not going to touch chemistry. market, of how big this it is large. we rely on antibiotics for a large part of the medical treatment that we live in. au can see how if we can find new way of treating some of these bugs, it can be massive demand. >> none of us want to live in a world where antibiotics do not work. that's a

a major pharma deal today as merck buys cubist pharmaceuticals for $8.4 billion.t merck's ceo told maria bartiromo earlier on this deal and why it made sense. >> it gives us a leadership position important area of marketplace where there are important economic trends. gerri: >> cubist shot up 35%. has you listened to our own charles payne weeks ago your portfolio would have big gains today. listen. >> i like the action on this chart. looks like the stock is building real nice base. it used to be resistance. now it is support. longer term i think it has potential $95. i wouldn't consider it a trading vehicle. longer term i do like it. david: with us the aforementioned charles payne. you saw this coming? >> yeah. i had a couple in this biotech space. it can be hit or miss but when you get biotechs end up with a billion dollar drug and end up with a nice juicy pipeline the dynamics business of change, these old school drug companies are using biotech as their farm team. give you an example, liz. in 2010 merck spent $11 billion on r&d. then it went to 8.5 billion. 8.2

, merck, and you will here more about that from julie. the company that is involved, it involved, it originated in the public health agency of canada. department of defense together involved. the trial was put on hold. people hold. people get confused about that. there were four individuals. that does not mean it is the end of the vaccine by any means. very common. we saw saw it in a significant proportion of people. you don't even have to give a live virus vaccine. the question is, what is that going to mean? that is why you have phase one trials. the proposed path,, and this has been in close collaboration with the liberian department of health officials, a randomized double-blind placebo-controlled and a trial in sierra leone with at least two and liberia and possibly one or maybe two in sierra leone. we are working with the cdc now. i want people to really appreciate that none of these have been shown to be effective. i think we we will get the chance to discuss. the distribution and a trial in which not everybody gets a a particular

then we're also watching dow component merck. now, this is a different picture.ubis hitting highs today, moving forward to buy cubis pharmaceuticals so they can get a grasp on these antibiotics that treat infection. this as we've had so many new threats for bacteria and the like. this is an $8.4 billion deal, cubist right now is up about 6%. so those are two with winners on a day where we've seen, liz, down arrows across the board. the dow is down about 110 points right now with energy as the big loser. back to you. liz: okay. nicole, we have some breaking news, and you might want to watch the stocks involved down on the floor. most people out there who don't want to pay their federal income tax, well, guess what? they're being joined by deutsche bank. lawsuits have been filed against deutsche bank and six other entities for engaging in an abusive scheme to avoid federal income taxes. basically, what he's saying, he alleges that in 2000 deutsche bank used underfunded shell companies to evade significant tax liabilities. the suit seeks to recover more than $190 mi

well, pharmaceutical giant merck says it will be buying cubes, advanced antibiotic research, deal worth about $8.4 billion. merck says it wants to focus on tackling so-called super bugs, that have developed a resistance to antibiotics. american airlines is getting a upgrade. the airlines says it is spending $2 billion to add seat to planes, better entertainment options, internet access. lounges will get a make over. past few years the airline had been focused on operational issues, while it merged with us airways. >>> and, if you have a sweet tooth in the morning, some good news. general mills is bringing back its beloved french toast crunch. serial discontinued in 2006. but general mills says it listened to quote passionate fans who flooded call centers begat heard thousands of signatures, in a on line petition, and created a facebook page dedicated to bringing the cereal back. ukee, erika, i've never had it. i think i need to try it. >> oh, you need that french toast crunch. >> you need the french toast. >> excellent! >> and the milk adder ward -- afterward? >> matter of fact, maybe i

. >> how many at merck? has 76,000 people. >> let's turn to some of the news over the weekend, an important back-and-forth in europe. never a dull moment. hans legos is in berlin and the dialogue has decidedly heated up. an importantis conversation, there was a quiet this week and so what was going on behind the scenes of the apparent quiet? >> angela merkel -- we don't know when but she gave an interview and that popped on sunday. merkel was harshly critical of vladimir putin saying he is causing difficulties and problems. hollandefrancois lended his plane for a two our meeting with mr. putin. the question is when did angela merkel give the interview -- we don't know if it was before or after he tried to visit and cool things down. either way you get the sense that angela merkel is fed up with putin and willing to talk about it publicly. >> she connected the dots in a way have-nots in another global she calledbetween them for what they are, destabilized by russia. what is the signal she is trying to send? >

now in collaboration also with merck. new rank company is the company evolved and originated in the public health company of canada. d.o.t. and mh id and public phase trials enrolled. hold because of arthritis. people get confused about that. there were four individuals with what was clear info -- inflammation. does not mean it was a vaccine by any means. significant proportion of people. the question is, what will that mean, and that is why your phase one trials, so you can investigate that pretty usually. are too.sed task this has been in very close collaboration with the library and department of health officials, the plan of a randomized double-blind trial in liberia and a step-wedged trial in sierra leone with at least and possibly one or maybe two in sierra lyons. we are working with the cdc to talk about that. i want people to really appreciate none of these have been shown to be affected. they have been given on compassion use and we do not know if any of them work. way theyigure out a may work or not but we'll ne

merck is said to be in talks to buy a startup for more than $7 billion.erck would pay about $100 per share. the deal could be done as early as this week. another company we are watching this morning, sony. the company reels from the hacking of its entertainment unit. it appears its playstation network may have also been targeted by hackers. here with more is caroline hyde. gamers couldn't access the playstation. you have to fill me and. how does it work? >> if you are using the network online, you found that from midnight hour time till about 2:30 this morning looking at u.k. time, already the connection problems have ended. they said everything is back up and running. they say they are currently investigating the cause. you were prevented from getting online if you wanted to play a game. you need an online connection. the people taking the credit, i guess, they were sending out tweets saying, psn login offline. this is just after they celebrate their 20th anniversary, the console maker. of course, after the north korea-related hack that drilled causingy

merck's ceo will join us live to tell us why and what's next.ging the broader market for much of the year this sector is on fire. currently one of the best performers we'll tell you which one it is ands the stocks that are fueling the rally. and what's going to give you a better long-term return. stocks or owning a home? we will break down the numbers. join the conversation at cnbc.com/vote. now back to my fellow suffering redskin fan scott wapner. >> thank you very much. >>> speaking of suffering twitter investors are doing just that again today. josh brown, talking about the fact that the stock is at another 5% today. what's going on? >> what is going on with the stock? >> it's cut in half from its 52-week high. you have it on the ipo you paid about 28, lost almost all of the benefit from having done that. it's 36 bucks. looks like it's headed lower. the former head of product is leaving. they demoted him in october. a lot of people said it's a matter of time before he leaves. he's gone. and i think there's just continued confusion over who ru

another big deal and merck is at it again. last 10, congress is facing a thursday deadline to finalize a spending bill and avoid another government shutdown like we had last year. it looks like cooler heads will a done but it is not deal. peter cook is with the latest. >> i will explain the key role they play in all of this, but thursday is the deadline to get the spending done. lawmakers head for home. the department of homeland security getting special treatment here, only getting funding into early 2015. that is part of the punishment for president obama for immigration executive action. do not know is what other goodies might be inside the legislation that democrats might object to. we already know there are about 70 of the policy riders on the table. here are some of the riders to watch today to see if they make the final cut. preventing the official wildlife service from putting the -- on the endangered list. barring the department of transportation from imposing trucker rules right away. nancy pelosi warning on friday t

they are dumb as a bag of hammers over there at merck. i can't. i'm too much of a diplomat and home depot fan to commit such an error. higher rates let them make huge amounts of money, billions. the key to this kind of thinking is the companies themselves say nothing. they don't tell you what plays they are going to run because these are big thing stories and xs and os on the board only. the bank spoke at a conference today and the news is the fourth quarter isn't looking so hot. the actual business is weak. the bank rally was stopped in its tracks, although the group did rally into the close. although both big banks, bank of america and citigroup, no, they didn't finish in the black. then there's mcdonald's. when i think of this company i imagine a quarterback about to be sacked again and again by blitzing safeties with europe and linebackers from europe and defensive tackles just mauing the company from america and from asia and i've got to tell you something, those regions are forcing mcdonald's to put up horrendous numbers. been wondering abou

merck, what can i tell you? is there science done at merck? >> i don't know.ume there is. >> is there science there? >> not sure what's going on there. >> that was the greatest sale. it's the snaple of medical. >> in five years from now, we can revisit this. >> let's take a longer term view. not unlike if you bought the ruble the day that they raised it to 17%. home run. so this could be the ruble. >> right now doesn't look so good. >> all right. let's switch to a company that's trying to do something. novonordisk. this is an injectable weight loss drug. most have been a bust. i always believe that anything that doesn't involve diet and exercise will be a bust. but obesity is a real issue in the world. if you could lower it somehow with a shot, obesity, leading cause of heart disease and diabetes. this could be a great break, if it really works. >> if it works. although, few of them really work. >> biotech is where you get the breakthroughs. but novo's done some good things. >> well, look, stock is up 5%. we'll be watching that one along with a bunch of others

i know you weren't happy about the merck deal and i have options that ended in january for 71. >> i think that merck, look, they obviously paid too much in light of what happened but it's great to be in antibiotics. health care sector is a good place to be on the way down, i stress on the way down because people realize there is real credit risk out there. let the stock come in and do buying. always keep an eye on the data that comes out of conferences. you have hot up and coming names that can run for a long time to come after the momentarily oil and cell gene, that is a favorite. there is much more "mad money" ahead, including how to cheaper feed your pup. a biotech breakthrough called isis as i just mentioned to really run. 50% move up but it is done or more to come? i got the ceo. >>> a nor'easter of calls on the way in a brand-new edition of the lightning round. stick with cramer. do you like to travel? i'm all about "free" travel, babe. that's what i do. [ female announcer ] fortunately, there's an easier way, with creditcards.com. compare hundreds of cards from every major bank and

merck paid to buy the company.he international continental hotel group sold the hotel in paris for 330 million euros. the deal has finally been agreed. the buyers agreed to invest 60 million in the hotel which first opens its doors in 1862. >> starbucks is eyeing new products, which might seem unlikely. >> they are trying to add a beer and wine to its offerings. this is according to an investor conference they held last week. they are trying to improve afternoon and evening trade in starbucks. they have a dip in the afternoon trade. the company is seeking to double its revenue to $4 billion by 2019. one billion of that is expected to come from beer and wine. >> pumpkin spice beer. [laughter] >> i think that has already been done. cnónóñóñóñóñóqm?xq/pç

i also love that merck ac significance today as well.t a company that got late stage drugs. look at the way merck traded. it was virtually unchanged for the balance of the day. it fits very, very well. that tells you what the street thinks about this. >> or you are seeing the street coming out this afternoon and earlier today with the numbers coming out, upgrading it and saying these guys have 29% over the next five years. the question is, does that price into the stock? so much good news has been priced in. granted, the last $40, they have been wrong. at this point, you can't tell me that these guys aren't saying the next $20 is going to be easier to get. i'm not sure. >>> still ahead, lulu lemon prepping for its earnings report. we will tell you why traders are expecting a double digit move in the stock. next. [horn honk] what's this? this is the ultimate mobile work station. you need an upgrade. this has everything. you can still do all those things with your new microsoft surface pro 3. it's light, powerful, and runs all the applicat

company like merck should break off the animal health. johnson & johnson has gotten rid of the divisions i felt were weaker. ibm i don't know what they would break themselves into. they can't be the company they want to be unless they stay together at the same time, they're getting their head beat in everywhere. they don't offer the level of value that people think they do. i'm not sure. one thing, i'm not running ibm. i think that would be a very difficult thing to do right now. >> it's steve. as we look back over our careers, there have been a number of cycles where mergering and acquiring was the thing to could and other cycles de-merging. as i look at yours list what strikes me about it, you don't need for them to break up because they're great companies with solid business models so it's like a win-win. if you own them they should participate in enough market and outperform in a down market because of the beta. if they break up you can get rich from it. is that the thought process on the stocks? >> what people are going after are com

. >>> and researchers suspended a clinical trial of a new ebola vaccine developed by merck and link geneticsuse fewer volunteers in the study [ozpx complained of pain in their hand and feet. the stock was down 19 cents finishing at $59.34. >>> even though more people have health insurance, a lot of americans are saddled w unpaidil a new government report said nearly 20% of all consumers, that's about 43 million people owe money for past medical care. the consumer financial protection bureau also says many people are confused by notices they get from hospitals and insurance companies about the cost of treatment. >>> the debt dilemma is becoming more dire for some americans. one in five say they never expect to get out of debt. sharon epperson with surprising statistics from a recent survey and money makes to make to keep debt from getting out of control. is the debt problem getting worse or better? >> it's worse since credit card did this survey in may of 2013, they saw double in percentage of americans who say they'll be in debt forever. they're now saying that 18% of the people who responde

merck is going to buy them. u.s.ets are holding after seven straight weeks of gains for the s&p 500. thisroducer is sad that does not look it's going to 18,000 today. let's show you what's happening overseas. this is the euro dollar exchange. the dollar is trading at a two-month high. it is trading at a five year high against the broader currencies. this is because of some data we had coming out overnight from china showing that chinese imports fell more than economists had expected. i should say unexpectedly fell. let's show you what is happening to the shanghai composite. there has been a run-up in chinese equities. it is up 24% in that month. it is truly incredible. now it has topped 3000 for the first time since 2011. this is the first time in three years. this was a big move over there in europe. we will get to russia. let's show you what is happening there right now. the ruble is a little bit stronger today. inre is a lot of speculation the market that the russian central bank this week is going 2.5 percent.tes

if you want big pharma i say take a hard look at merck. whether the return of cold war politics or concerns about china we live in a complex world. lucky for you there are companies to count on. much more money ed including the company behind the comfortable ugg boots. everyone wants them under the tree. if you think the holiday season is just about the lowest price? you need to hear what the ceo has to say. all of the shopping making you hungry? i have the restaurant stock to satisfy your craving. plus all of your calls in the new edition of the lightning round. stay are cramer. here's a question for you: when electricity is generated with natural gas instead of today's most used source, how much are co2 emissions reduced? up to 30%? 45%? 60%? the answer is... up to 60% less. and that's a big reason why the u.s. is a world leader in reducing co2 emissions. take the energy quiz -- round 2. energy lives here. >>> let me tell you why you should pay attention when i interview a ceo on "mad money." five weeks ago deckers brands, maker of ugg b

in edmonton in just last month taking over 32 percent we took profits after the news of merck acquiringy. and to have some profits on its a lot of people jumped on that bandwagon. said to have another retail winner the stock popped it is that since i mentioned it but to check out the pros and a great way to cash in on capitalism. the stock is doing well but it has been downgraded and i thought a convoluted reason. you still likes the stock? >> that is what they're trying to get back to they beat off the bottom line. and a 5% increase i still like it. >> this is gore traders or investors? >> it is long term. now there is the organic food play? they are doing extraordinarily well. anybody they want to chase? >> that organic food market is customers it is here to stay. expect the the etfs growth rate they also reiterated guidance i love to stop. charles: writers systems? that has held up pretty well we have more than one good month of economic data people will start to move just in time for summer. to where they have no taxes. >> at the time it was the pick on in america and now be as chea

and pointing a finger at merck, writing that growing tolerance of violence and warfare has also playedhe book is "a call to action >>>action ." i talked to him and asked him what inspired him? >> they have had programs of an active nature in 79 different countries, and since i left the white that's what we have been doing. and we have gotten to know people in all kinds of nations, particularly in third world countries where women and girls are abused. but the people who can do something about it now have 23 recommendations in the book to help solve these problems but particularly in the rich world like the united states. and a lot of the problems occur in the poorest countries, but are also present here in the united states. for instance slavery, the slavery scene is much greater than it was during the 19th century when black people were brought out of africa for slavery. there is about $32 billion worth of human trafficking every year. and the state department now is required to report on this annually, and they reported last year that 800,000 people were sold across international bor

what can i say about merck other than through the equivalent of a pick six right into richard sermon'sn honor of the touchdown and there is mcdonalds. when i say mcdonalds, it's going down. i'm yelling chamber. you better move, you better danc dance. >> ooooo, ooooo, oooo i'm going down. >>> that song? >> got it. >> exactly. >> how did you know that? >> i got kids. >> holy cow. >> probably did finally get into your head. >>> before we get to your tweets, time for homework. jeremy in new york called about xon. i said i would get back to him. it's a biotech who is a leader in synthetic diverse n markets including health care, food, energy and environmental science and can grow at a rapid 78% compound rate through 2018 plus the company is run by a proven management team with a track record of building and commercializing r and d driven businesses including new river pharmaceuticals sold for 2.6 billion and clinical data sold for 1.2 billion. i bet they can do the same. i think the stock sounds good. maybe a little weakness from oil. buy it. next up on november 5th. jeff in michigan asked

j & j, merck, pfizer. 3m, as well. >> beaten down -- well, i shouldn't say beaten down. exxon and chevron. oil prices are climbing today. our jackie deangelis is keeping an eye on how oil is trading. >> good afternoon, guys. a lot of traders saying that the market leading the energy complex higher today. we did see wti up $1.86 settling at $57.12. brent crude around $62 and traders saying you have to take a step back here. this is a pause right now. from probably steeper selling pressure that will come back in the new year. they're taking a cautious tone to this momentum right now because they still say it's a supply/demand story and one of our go-to guys pulled stats. eia forecasting demand to increase by 900,000 barrels a next year. but you have got iraqi supply, libyan supply and u.s. supply still steadily increasing. supply going up and first quarter, second quarter probably still seeing an imbalance and that probably will add some pressure to these prices. don't get too excited about the lift just yet and for you oil geeks, you both are -- we dropped another penny.

>> whose. >> frazier, merck's. >> i don't think we should do that. stay away.l a few minutes from now. >>> we'll have a live interview with alcoa's ceo klaus kleinfeld. we'll be back on "squawk on the street." >>> you're watching cnbc's "squawk on the street," live from the financial capital of the world. the opening bell in a few minutes, after a rough week last week, to say the least. 700 points on the dow to the downside, biggest loss in three years. friday's volume, down here, the biggest since halloween, as we closed offly close to lows. and ten-year we'll watch, biggest drop in yield in two years. deutsche out saying it's going below two. >> that changes -- banks were trying to make a stand, they need higher rates and they were rebuffed in the last day. friday was -- i was going over this within where the oils could go, going back to where they were in 2008. some of these, 2009, really the low. all of these could go. halliburton went to 20, schlumberger went to 50. noble, a nice article about israel, 28. exxon went to 60. chevron went to 64. marathon went

biggest laggers are verizon and merck. over to melissa lee in las vegas for a news alert. >> i'm melissa lee here in las vegas where the stage is set in las vegas for what could be a very interesting showdown between mark cuban and christopher cox. now, this will be the first time the two men have met since cuban was cleared of charges in the mama.com case. and that case alleged cuban had dumped about $8 million in soft on information he obtained from the ceo. cuban was cleared of all charges, but it propelled him to the forefront of all s.e.c. critics and he's been vocal about the ineptitude of the s.e.c.. essentially said the s.e.c. lies, they're in for wins. and that there is a lack of awareness at the agency. so there could be some very choice words between 2450es two men. of course tune into cnbc for all the highlights as they happen. and of course later on on the "closing bell," i'll have an exclusive interview with mark cuban. tyler, over to you. >> thank you very much for that. it will be lively. in the meantime, l

even bio techs held on to the back of the news and from cubist pharmaceuticals being taken out by merck the bio techs have come off of their highs although for the moment they are holding up there. back to you. >> thank you very much. let's round it out with oil. jackie deangelis live. give us more facts. >> let's look at prices here. we are looking at wti, the 63 handle. the last time we saw that was december 1. we briefly touched at 63.72. now we are below that point. it is the key technical levels when the pressure starts to intensify and they don't want to be caught holding the bag. you are looking at brent crude with a 63 handle. a lot of traders saying the saudis put this out that we will stabilize around 60. we have to get there first. certainly this is the leg down. two things to watch, the morgan stanley forecast of $70 brent for 2015 also adding pressure to the market and bp saying it will speed up job cuts here in the u.s. and overseas as a result of the oil price decline that we have seen over the last few months. of course, people get nervous when they hear this because whe

nike, united health, pfizer, merck, and johnson & johnson.h care is stinking up the joinlt. >> and s&p 500 at 2085. we might get the 51st record close of 2014, brian. >> wonderful. by the way, you're here friday. i am not. so, mandy -- merry christmas. as my little cousin tim used to say, god bless us every one. >> that's really nice. thanks, little tim. thank you for watching "street signs," happy. as we say in australia. happy christmas. stay safe, everybody. >>> and welcome to "the closing bell." i'm kelly evans at the new york stock exchange. reveal the headline now, bill? 18,000 on the dow jones industrial average. >> we did it. we have crossed and took seven months to do -- six or seven months from 17,000 to 18,000. so there we have. first time ever breaking that milestone and now we just wait to see if we can close above that for the first time ever. remember, any positive close for the dow or s&p will be a new record. >> it's not getting the fan fare today b

also could be a strong exert of merck's vaccine which is currently the only product on the market. million dollars. four times its normal volume. check out that trading action. back to you do. >> dow close to session highs here. about ten points away. we were at 279 at the top. social stocks on the move. groupon shlg pandora, linkedin seeing some love. >> microsoft having a nice pop today. oracle itself up better than 8% still today. >> linkedin of course moving on the back of a wells fargo upgrade. outperform is where they initiated coverage. good international growth especially in china but early in the space risk is on. >> yes. of course the following the fed day, can't forget too it is an expiration week. and if cashin were here he would say december expiration tend to be one of the more favorable for the bulls. let's get to scott wapner and the half. ♪ >>> welcome to the halftime show. let's meet the starting lineup. stephanie link, josh brown, jon najarian, and robert sechan is with us from ubs, private wealth management. and a baron's top 100 financial advisers and ben willi

some breaking news in from geneva about a very important clinical trial of a vaccine by the company mercks trial has been interrupted, and the reason we're hearing is that all 49 volunteers in geneva have been taken out of the program for the moment. it's a measure of precaution, because four of the patients complained of joint paints in their hands and feet. apparently they are all fine, and the human safety trials are due to resume in january. thanks so much for being with us here on "gmt." yalda's here next with "impact." zapped it, right to our house. and that's how they got it here. so, santa has a transporter? for the big stuff ... and it's a teleporter. cool. the magic of the season is here, at the lexus december to remember sales event. this is the pursuit of perfection. yeah so with at&t next you get the new iphone for $0 down. zero down? zilch. nothing. nada. small potatoes. no potatoes. diddly squat. big ol' goose egg. the new iphone, zero down. zero. zilch. said that already. zizeroni. not a thing. zamboni. think that's a hockey thing. you know what, just sign us up. okay - th

official told merck look, the president still feels it was the right decision to try to rescue somersout his location was reliable, he was in that exact location. in a statement yesterday, president obama said "the u.s. would spare no effort to use all of its military intelligence and diplomatic capabilities to bring americans home safely wherever they are located." meanwhile, steve, we are also hearing from his friends and his colleagues today in a statement, his stepmother describes somers as a talented photographer with a sensitive for the people and people's lives. i spoke with one of his colleagues who works at pbs news hour but who had spent some time in yemen as well, steve. that person telling me that he just can't believe that this happened to luke somers. that entire community of people who are his friends and his family just in shock this morning. steve? >> all right, kristen welker live at the white house. thanks for joining us this morning much appreciate that. >> absolutely. thanks. >>> we are joined nowby retired u.s. army general, wesley clark, former supreme allied co

>>george: merck tracking how hot spot this morning's highway 17 is set down and of corrections northboundthere are down trees and power lines and that is a reason why traffic is being turned around south lawn and some of our lesser law with no indication of where the roadway will be reopened. >> reporter: after their daughter got a new heart disease johnson was close to dying after being diagnosed with a heart condition last year she was even too sick to get all the transplant list she was healthy enough to get back on track and at less one of the three months to find a donor heart but this past october she got her new part in her recovery to the doctors to the hospitals and stanford stanford and the family gave the heart. have they fall because they gave me a second chance at life. last year were busily working on what if we had to concentrate. she was able to get her new artist of five cfa retain the san francisco giants to win the world series they're celebrating the same she said she even credits a quick recovery to the giants. >> james: following your forecast will have a radar showi

they went into the meeting with the italians and french pushing back against angela merck whole saidshould do more to sort out their budgets. as far as the week ahead the big news will be this cheap debt from the central bank, the ltro. they're going to basically announce that on tuesday and allot it on thursday and that will feed into the discussion about the balance sheet. let's leave it there for now. >> thank you very much. >>> president obama sitting down with prince william in the oval office a few moments ago. the pins and his wife are on a three-day tour of the states. later in the week they will attend a nets game, cleveland cavs game at the barclay center in brooklyn. expected to hang with beyonce and jay-z and visiting the 9/11. >> lebron action too. >> we will see about that. he will be in the building. >> absolutely. >> when we come back, everyone is missing one key detail when it comes to shares of apple, so says jim at citi. he's with us to explain in a moment. right now, you can get a single line with 3 gigs for $65 a month. 3 gigs ... is that a lot? that's about...10

that's been what the long ride down's been for old line pharmaceuticals like merck or similarly hobbledke mcdonald's or general mills. when you see multiple compression beginning don't hang on for the full ride down. just -- >> sell, sell sell sell! >> to build a portfolio that can work in any market you need a fast grower preferably a secular growth stog that still has lots of runway ahead of it for years to come. and remember when you're dealing with growth it's worth it to pay up for a company that's still accelerating. it's worth selling a zel raittor very quickly, dump it, because once the momentum starts to slow down it can shrink for ages before it bottoms. and most paibts patients can't hold out that long. mohammed in texas. mohammed. >> caller: hello, jim, how's it going? >> all right. how are you? what's up? >> caller: my question is i am a new college graduate. i graduated from college for a year now been in the workforce and i invested in a 401(k) in my outside brokerage account and was wondering how should i partition my investment in each account and what my investment par